Discover investment opportunities in Top 30 Stocks Under $9 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 30 Stocks Under $9 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top 30 Stocks Under $9 using our Smart AI Filter.
10 stocks found for "Top 30 Stocks Under $9"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.26 Risk measure | ±56.0% Price volatility | -61.7 Valuation | 0.00% Annual yield | |||
1.73 Risk measure | ±64.4% Price volatility | 28.8 Valuation | 0.00% Annual yield | |||
0.44 Risk measure | ±100.0% Price volatility | -0.4 Valuation | 0.00% Annual yield | |||
1.17 Risk measure | ±100.0% Price volatility | -4.1 Valuation | 0.00% Annual yield | |||
0.76 Risk measure | ±96.1% Price volatility | -12.0 Valuation | 0.00% Annual yield | |||
0.79 Risk measure | ±46.9% Price volatility | -62.2 Valuation | 0.00% Annual yield | |||
2.28 Risk measure | ±93.4% Price volatility | -775.0 Valuation | 0.00% Annual yield | |||
1.12 Risk measure | ±67.2% Price volatility | 8.2 Valuation | 0.00% Annual yield | |||
1.19 Risk measure | ±71.0% Price volatility | -1.1 Valuation | 0.00% Annual yield | |||
1.19 Risk measure | ±88.4% Price volatility | -5.2 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What industries do stocks like ATAI and IMUX belong to on this page?
A: ATAI and IMUX are part of the biotechnology and pharmaceuticals sector. This sector focuses on developing and commercializing healthcare treatments and innovative therapies, often crucial during healthcare advances and pandemics.
Q: Is it common for stocks under $9 like CDE and UEC to involve natural resource extraction?
A: Yes, CDE, specializing in precious metals, and UEC, focusing on uranium, operate in the resource extraction sector. Companies in this sector can attract investors seeking exposure to commodity price fluctuations.
Q: What is a typical risk for stocks such as NXE located in the mining industry?
A: NXE, involved in uranium mining, faces risks including commodity volatility, regulatory changes, and environmental concerns. These factors can impact production costs and profitability.
Q: How do companies like VNET contribute to the technology sector?
A: VNET is part of the technology sector, specifically focusing on data center services. This contributes to cloud computing growth and digital infrastructure, essential for business digital transformation.
Q: Do stocks like WRN involve long-term investment considerations?
A: Yes, WRN, in the mining sector, involves long-term considerations due to lengthy development timelines, permitting processes, and potential environmental impact assessments preceding production.
Q: Are there any competitive advantages for stocks like QNCX in pharmaceuticals?
A: QNCX, a pharmaceutical company, may have competitive advantages through proprietary technology, patents, or unique drug formulations, helping distinguish it within a crowded market.
atai Life Sciences (ATAI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Read moreThe mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 231.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read moreThe FDA has notified Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) that it may proceed with Phase 3 trial of its lead candidate, brilaroxazine, a serotonin and dopamine receptor modulator for schizophrenia. The FDA has also signed off an additional Phase 3 trial focused on the long-term safety of brilaroxazine in patients with schizophrenia.
Read more